Clinical trials: All Malignancies
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Lymphoblastic, Acute, ALL, Childhood
Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It occurs when a bone marrow cell develops errors in its DNA. Certain tests are used to help detect the disease.
- Trial name
- NCT03627208
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
ALL, Childhood, Behavior, Health
Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL
The purpose of this study is to conduct a single arm pilot of the NOURISH-ALL (Nourishing Our Understanding of Role modeling to Improve Support and Health in Acute Lymphoblastic Leukemia) intervention focused on three components…
- Trial name
- NOURISH-ALL (NCT06050850)
- Testing
- NOURISH-ALL
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Trial name
- QUATRO-APL (NCT07504458)
- Testing
- QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 150 people
- Sponsor
- Quetzal Therapeutics
Burkitt's Lymphoma, Lymphoblastic Lymphoma
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
The goal of this clinical research study is to find the highest tolerable dose of the drugs clofarabine and cyclophosphamide that can be given together in the treatment of relapsed or refractory ALL.
- Conditions
- Burkitt's Lymphoma, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT00412243
- Testing
- Clofarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with…
- Conditions
- Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
- Trial name
- FLASHLITE (NCT05025774)
- Testing
- Physical activity
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Acute Lymphoblastic Leukemia
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL.
- Trial name
- NCT04129099
- Testing
- GC022F
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00032149
- Testing
- bleomycin sulfate, filgrastim, cyclophosphamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Lymphoma Trials Office
Multiple Myeloma
Daratumumab in Combination With ATRA
Multiple myeloma (MM) patients who develop bortezomib and lenalidomide-resistant disease have a very poor survival of only a median of 9 months, indicating that new agents are urgently needed.
- Trial name
- DARA/ATRA (NCT02751255)
- Testing
- all-trans retinoic acid (ATRA)
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Hematologic Neoplasm, HIV Infection
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
This study will investigate the safety and effectiveness of a new stem cell transplant procedure to treat acute or chronic leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin's and non-Hodgkin's lymphoma in HIV-infected…
- Trial name
- NCT00005785
- Testing
- GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer, Pediatric Cancer
CAYA Cancer Prospective Cohort Study
Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited.
- Conditions
- Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT07632014
- Where
- 6 sites in Armenia, Egypt and 3 more
- Volunteers
- 6,000 people
- Sponsor
- Resonance, Inc.
Leukemia, Lymphoma
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00004114
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
This phase I trial is studying the side effects and best dose of vorinostat and decitabine in treating patients with relapsed, refractory, or poor-prognosis hematologic cancer or other diseases.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00357708
- Testing
- decitabine, vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Adult patients with r/r acute lymphoblastic leukemia (ALL) (stratum I), r/r Non-Hodgkin's lymphoma (NHL) including chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) or mantle…
- Conditions
- Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03676504
- Testing
- CD19.CAR T Cells, Fludarabine, Cyclophosphamide
- Where
- 2 sites in Germany
- Volunteers
- 68 people
- Sponsor
- University Hospital Heidelberg
Leukemia
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias.
- Trial name
- NCT00882076
- Testing
- Clofarabine, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Milton S. Hershey Medical Center
Acute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
This is a pilot study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in patients with relapsed or refractory CD19+ leukemia and lymphoma that was previously treated with cell therapy.
- Trial name
- NCT02374333
- Testing
- huCART19
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania